GB202019663D0 - Predictive biomarkers for risk of bladder cancer in diabetes patients - Google Patents

Predictive biomarkers for risk of bladder cancer in diabetes patients

Info

Publication number
GB202019663D0
GB202019663D0 GBGB2019663.0A GB202019663A GB202019663D0 GB 202019663 D0 GB202019663 D0 GB 202019663D0 GB 202019663 A GB202019663 A GB 202019663A GB 202019663 D0 GB202019663 D0 GB 202019663D0
Authority
GB
United Kingdom
Prior art keywords
risk
bladder cancer
diabetes patients
predictive biomarkers
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2019663.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Randox Laboratories Ltd
Original Assignee
Randox Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Randox Laboratories Ltd filed Critical Randox Laboratories Ltd
Priority to GBGB2019663.0A priority Critical patent/GB202019663D0/en
Publication of GB202019663D0 publication Critical patent/GB202019663D0/en
Priority to PCT/EP2021/085424 priority patent/WO2022128881A1/fr
Priority to EP21839081.3A priority patent/EP4260067A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB2019663.0A 2020-12-14 2020-12-14 Predictive biomarkers for risk of bladder cancer in diabetes patients Ceased GB202019663D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2019663.0A GB202019663D0 (en) 2020-12-14 2020-12-14 Predictive biomarkers for risk of bladder cancer in diabetes patients
PCT/EP2021/085424 WO2022128881A1 (fr) 2020-12-14 2021-12-13 Biomarqueurs prédictifs du risque de cancer de la vessie chez des patients atteints de diabète
EP21839081.3A EP4260067A1 (fr) 2020-12-14 2021-12-13 Biomarqueurs prédictifs du risque de cancer de la vessie chez des patients atteints de diabète

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2019663.0A GB202019663D0 (en) 2020-12-14 2020-12-14 Predictive biomarkers for risk of bladder cancer in diabetes patients

Publications (1)

Publication Number Publication Date
GB202019663D0 true GB202019663D0 (en) 2021-01-27

Family

ID=74189020

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2019663.0A Ceased GB202019663D0 (en) 2020-12-14 2020-12-14 Predictive biomarkers for risk of bladder cancer in diabetes patients

Country Status (3)

Country Link
EP (1) EP4260067A1 (fr)
GB (1) GB202019663D0 (fr)
WO (1) WO2022128881A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297165B6 (cs) 1997-04-21 2006-09-13 Randox Laboratories Ltd. A British Company Of Ardmore Zpusob výroby zarízení s pevnou fází k provádení multianalytních rozboru

Also Published As

Publication number Publication date
EP4260067A1 (fr) 2023-10-18
WO2022128881A1 (fr) 2022-06-23

Similar Documents

Publication Publication Date Title
WO2008104543A3 (fr) Procédé de prévision de l'occurrence de métastases chez des patients souffrant de cancer du sein
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
SG10201405975VA (en) Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
IL289787A (en) Antibody combinations for cancer treatment in specific patients
EP4168933A4 (fr) Prédiction de naissance prématurée
IL313628A (en) Cell therapy for diabetes
GB202019663D0 (en) Predictive biomarkers for risk of bladder cancer in diabetes patients
GB201905111D0 (en) Novel biomarkers and diagnostic profiles for prostate cancer
GB202103080D0 (en) Cancer biomarkers
EP4030993A4 (fr) Améliorations apportées à des soins de santé personnalisés destinés à des patients atteints de troubles de la motricité
IL304353A (en) Hydrogels for cellular therapy
EP4093289A4 (fr) Prédiction de biomarqueurs à l'aide d'une tomographie par cohérence optique
EP4196771A4 (fr) Nanomarqueurs sers et kit de diagnostic de détection de biomarqueurs du cancer du sein
CR20120076A (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
IL314322A (en) Methods of treating patients with autoantibody-mediated disease
GB201915464D0 (en) Novel biomarkers and diagnostic profiles for prostate cancer
EP3775282C0 (fr) Biomarqueurs pour le traitement du diabète
EP4212174A4 (fr) Biomarqueur permettant de prédire la réponse à un traitement contre le cancer
EP4059954A4 (fr) Procédé, kit et biomarqueur pour aider au diagnostic du cancer du côlon
GB202206257D0 (en) Biomarkers of diabetic nephropathy
EP4203921A4 (fr) Biomarqueurs d'arnm pour le diagnostic d'une maladie du foie
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001573A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
IL304550A (en) Biomarkers for fimpinostat therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)